Plasma cytokines in TSC patients with daily 5 or 10 mg everolimus for 48 weeks reflected decreased VEGF-D, decreased collagen type IV, and increased VEGF-A after 24 weeks that was maintained at lower levels through treatment [57]. The gene discussed is VEGFD; the disease is tuberous sclerosis.